Mikhail I. Kotlov

Mikhail I. Kotlov

Auto-generated profile, based on publicly available information

Mikhail I. Kotlov

Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences, Vavilov Street, 32, Moscow, 119991, Russia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2017 in IUBMB Life
Verified
Journal Article
Open access
PDF file
VKVitalia Kulikova
Vitalia Kulikova
EMElena A. Morozova
Elena A. Morozova
SRSvetlana Revtovich
Svetlana Revtovich
MKMikhail I. Kotlov
Mikhail I. Kotlov
NANatalya Anufrieva
Natalya Anufrieva
TDTatyana V. Demidkina
Tatyana V. Demidkina
The exploitation of methionine‐depleting enzyme methionine γ‐lyase (MGL) is a promising strategy against specific cancer cells that are strongly dependent on methionine. To identify MGL from different sources with high catalytic activity and efficient anticancer action, we have expressed and characterized MGL from Clostridium novyi and compared its catalytic efficiency with the previously studied MGL from Citrobacter freundii. The purified recombinant MGL exhibits kcat and kcat/Km for methionine γ‐elimination reaction that are 2.4‐ and 1.36‐fold higher than C. freundii enzyme, respectively, whereas absorption, fluorescence, and circular dichroism spectra are very similar, as expected on the basis of 87% sequence identity and high conservation of active site residues. The reactivity of cysteine residues with DTNB and iodoacetamide was investigated as well as the impact of their chemical modification on catalytic activity. This information is relevant because for increasing bioavailability and reducing immunogenity, MGL should be decorated with polyethylene glycol (PEG). It was found that Cys118 is a faster reacting residue, which results in a significant decrease in the γ‐elimination activity. Thus, the protection of Cys118 before conjugation with cysteine‐reacting PEG represents a valuable strategy to preserve MGL activity. The anticancer action of C. novyi MGL, evaluated in vitro against prostate (PC‐3), chronic myelogenous leucemia (K562), and breast (MDA‐MB‐231 and MCF7) cancer cells, exhibits IC50 of 1.3 U mL−1, 4.4 U mL−1, 1.2 U mL−1, and 3.4 U mL−1, respectively. A higher cytotoxicity of C. novyi MGL was found against cancer cells with respect to C. freundii MGL, with the exception of PC‐3, where a lower cytotoxicity was observed. © 2017 IUBMB Life, 69(9):668–676, 2017

1 July 2012 in Doklady Biochemistry and Biophysics
Verified
Journal Article
Closed access
PDF file
SRSvetlana Revtovich
Svetlana Revtovich
EMElena Morozova
Elena Morozova
NANatalya Anufrieva
Natalya Anufrieva
MKM. I. Kotlov
M. I. Kotlov
YBYu. F. Belyi
Yu. F. Belyi
TDT. V. Demidkina
T. V. Demidkina

1 April 2021 in Protein Expression and Purification
Verified
Journal Article
Closed access
VKVitalia Kulikova
Vitalia Kulikova
NANatalya V. Anufrieva
Natalya V. Anufrieva
MKMikhail I. Kotlov
Mikhail I. Kotlov
EMElena A. Morozova
Elena A. Morozova
VKVasiliy S. Koval
Vasiliy S. Koval
TDTatyana V. Demidkina
Tatyana V. Demidkina